meningococcal group B vaccine

(redirected from Bexsero)

meningococcal group B vaccine

(me-nin-go-kok-al groop B vax-seen),


(trade name),


(trade name)


Therapeutic: vaccines immunizing agents
Pharmacologic: antigens
Pregnancy Category: B


Bexsero—Provides active immunization against invasive meningococcal disease caused by 3 strains of Neisseria meningitidis serogroup B (strains prevalent in the US). Tremenba—Provides active immunization against invasive meningococcal disease caused by 4 strains of Neisseria meningitidis serogroup B (strains prevalent in the US).


Induces production of antibodies to several strains of serogroup B Neisseria meningitidis.

Therapeutic effects

Prevention of invasive meningococcal disease.


Absorption: Well absorbed following IM administration.
Distribution: Unknown.
Metabolism and Excretion: Unknown.
Half-life: Unknown.

Time/action profile (antibody response)

IMwithin 2 mounknownunknown


Contraindicated in: Severe allergic reaction to a previous dose; Latex allergy (Bexsero tip caps contain latex).
Use Cautiously in: Geriatric: Safe and effective use in patients >65 yr has not been established; Lactation: Use cautiously if breastfeeding; Obstetric: Use during pregnancy only if clearly needed; Pediatric: Safe and effective use in children <10 yr not established (>90% risk of fever in infants <12 mo).

Adverse Reactions/Side Effects

Central nervous system

  • fatigue (most frequent)
  • headache (most frequent)


  • nausea (most frequent)
  • diarrhea
  • vomiting


  • injection site reactions (most frequent)


  • arthralgia (most frequent)
  • mylagia (most frequent)


  • allergic reactions including anaphylaxis
  • chills (most frequent)
  • fever
  • syncope


Drug-Drug interaction

Concurrent use of immunosuppressives may ↓ the desired immune response.



Intramuscular (Adults and Children 10–25 yr) Two 0.5 ml doses one mo apart.


Intramuscular (Adults and Children 10–25 yr) 0.5 ml followed by a second dose 2 mo later and a third dose 4 mo after the second dose.


Suspension for IM injection (Bexsero tip caps contain latex): 0.5 ml in pre-filled syringes

Nursing implications

Nursing assessment

  • Monitor for signs and symptoms of allergic reaction (dyspnea, rash, hives, swelling of face, lips, or throat). Keep epinephrine, an antihistamine, and resuscitation equipment close by in the event of an anaphylactic reaction.
  • Assess for latex allergy. Bexsero tip cap contains latex.
  • Assess for syncope. Make patient is sitting or lying down during and immediately following injections.

Potential Nursing Diagnoses

Risk for infection (Indications)


  • Intramuscular: Shake syringe vigorously for a homogenous white suspension; do not use if solution has separated, discolored, or contains particulate matter. Administer 0.5 mL IM into deltoid muscle of upper arm. Do not mix with other vaccines in same syringe.

Patient/Family Teaching

  • Explain purpose of vaccine to patient/parent. Emphasize need for 2 doses of immunization series for Bexseroor 3 doses for Tremenba.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

  • Prevention of invasive meningococcal disease including meningitis.
References in periodicals archive ?
We look forward to the important additional data that will come out of the UK routine infant immunisation programme with Bexsero, which may enable countries to have different scheduling options in the future.
Beginning on September 1, 2015, a novel, protein-based, multicomponent vaccine, Bexsero (GSK Vaccines, Siena, Italy), has been offered as part of the routine immunization program in the United Kingdom; the vaccine is given to infants in 3 doses at 2, 4, and 12 months of age (https://www.
Medics are urging parents to buy liquid infant paracetamol for babies being immunised with Bexsero, which is available from Tuesday, warning the fever could last a few days.
Washington and Sunderland West MP Sharon Hodgson had written to Health Secretary Jeremy Hunt after the Joint Committee on Vaccination and Immunisation vetoed the new drug Bexsero from being added to the list of vaccinations available free of charge for all children last summer.
The new drug, Bexsero, is the first Meningitis B vaccine licensed for use in the UK and could save thousands of lives.
The subsequent vaccination campaign with a two-dose series of the 4CMenB vaccine Bexsero targeted the 5,241 undergraduates and 541 graduate students living in the dorms, plus 6 caregivers or spouses of these students living in the dorms and 11 other individuals at the university with a medical condition putting them at high risk.
It is wonderful to see advances being made in the fight against meningitis and the news that the meningitis B vaccine Bexsero is now available in Ireland.
Bexsero, the first Meningitis B vaccine licensed for use in the UK, could save thousands of lives.
Everyone at Meningitis UK was touched to read that Vivienne is calling for the new Meningitis B vaccine, Bexsero, to be available on the NHS.
Firstly, we will use functional (bactericidal) monoclonal antibodies to map the most protective epitopes on the 3D structures of two key MenB antigens, fHbp and NadA, which contribute strongly to our recently-approved 1st generation MenB vaccine, Bexsero (O Ryan, 2014).
It confirms that the vaccine, two-dose Bexsero, is highly efficacious and can be used in outbreak situations.